KR20250022143A - 피미테스핍을 함유하는 의약 조성물 - Google Patents

피미테스핍을 함유하는 의약 조성물 Download PDF

Info

Publication number
KR20250022143A
KR20250022143A KR1020257000541A KR20257000541A KR20250022143A KR 20250022143 A KR20250022143 A KR 20250022143A KR 1020257000541 A KR1020257000541 A KR 1020257000541A KR 20257000541 A KR20257000541 A KR 20257000541A KR 20250022143 A KR20250022143 A KR 20250022143A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
crystalline cellulose
manufactured
mass
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257000541A
Other languages
English (en)
Korean (ko)
Inventor
데츠야 니시야마
유우이치로우 니키
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20250022143A publication Critical patent/KR20250022143A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257000541A 2022-06-10 2023-06-09 피미테스핍을 함유하는 의약 조성물 Pending KR20250022143A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2022-094420 2022-06-10
JP2022094420 2022-06-10
PCT/JP2023/021535 WO2023238929A1 (ja) 2022-06-10 2023-06-09 ピミテスピブを含有する医薬組成物

Publications (1)

Publication Number Publication Date
KR20250022143A true KR20250022143A (ko) 2025-02-14

Family

ID=89118411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000541A Pending KR20250022143A (ko) 2022-06-10 2023-06-09 피미테스핍을 함유하는 의약 조성물

Country Status (10)

Country Link
US (1) US20250312280A1 (https=)
EP (1) EP4537824A1 (https=)
JP (1) JPWO2023238929A1 (https=)
KR (1) KR20250022143A (https=)
CN (1) CN119365195A (https=)
AU (1) AU2023282693A1 (https=)
CA (1) CA3258968A1 (https=)
MX (1) MX2024015327A (https=)
TW (1) TW202404585A (https=)
WO (1) WO2023238929A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004610A1 (ja) 2009-07-10 2011-01-13 大鵬薬品工業株式会社 アザ二環式化合物又はその塩
WO2015046498A1 (ja) 2013-09-30 2015-04-02 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん併用療法
WO2016181990A1 (ja) 2015-05-12 2016-11-17 大鵬薬品工業株式会社 アザ二環式化合物の結晶
WO2019004417A1 (ja) 2017-06-30 2019-01-03 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん化学療法
WO2019054465A1 (ja) 2017-09-15 2019-03-21 大鵬薬品工業株式会社 Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤
WO2019221086A1 (ja) 2018-05-14 2019-11-21 大鵬薬品工業株式会社 アザ二環式化合物による悪性腫瘍の治療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4608087B2 (ja) * 1999-12-22 2011-01-05 富山化学工業株式会社 固形製剤の製造法
EP2498759B1 (en) * 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
JP6918204B2 (ja) * 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004610A1 (ja) 2009-07-10 2011-01-13 大鵬薬品工業株式会社 アザ二環式化合物又はその塩
WO2015046498A1 (ja) 2013-09-30 2015-04-02 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん併用療法
WO2016181990A1 (ja) 2015-05-12 2016-11-17 大鵬薬品工業株式会社 アザ二環式化合物の結晶
WO2019004417A1 (ja) 2017-06-30 2019-01-03 大鵬薬品工業株式会社 アザ二環式化合物を用いたがん化学療法
WO2019054465A1 (ja) 2017-09-15 2019-03-21 大鵬薬品工業株式会社 Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤
WO2019221086A1 (ja) 2018-05-14 2019-11-21 大鵬薬品工業株式会社 アザ二環式化合物による悪性腫瘍の治療法
WO2019220512A1 (ja) 2018-05-14 2019-11-21 大鵬薬品工業株式会社 アザ二環式化合物による悪性腫瘍の治療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clin Can Res 15, 9-14 (2009)
Nat. Rev. Cancer, 5 : 761-772 (2005)
TRENDS Mol. Med., 10 : 283-290 (2004)

Also Published As

Publication number Publication date
CA3258968A1 (en) 2025-04-18
EP4537824A1 (en) 2025-04-16
TW202404585A (zh) 2024-02-01
CN119365195A (zh) 2025-01-24
WO2023238929A1 (ja) 2023-12-14
US20250312280A1 (en) 2025-10-09
MX2024015327A (es) 2025-02-10
AU2023282693A1 (en) 2025-01-02
JPWO2023238929A1 (https=) 2023-12-14

Similar Documents

Publication Publication Date Title
EP2331074B1 (en) Granulates, process for preparing them and pharmaceutical products containing them
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
EP2729130B1 (en) Darunavir combination formulations
JPWO2002024166A1 (ja) 崩壊性が良好な経口製剤
TWI790364B (zh) 包含烷基硫酸鈉之醫藥組合物
KR20100099113A (ko) 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
JP5318400B2 (ja) レボフロキサシン含有錠剤
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
EP4048276B1 (en) Solid pharmaceutical formulations comprising ticagrelor
JP2022532540A (ja) アキシチニブを含有する医薬組成物
US9248102B2 (en) Tablet containing 5-hydroxy-1H-imidazole-4-carboxamide
JPWO2020090970A1 (ja) 抗腫瘍剤を含む医薬組成物
EP3697392B1 (en) Tablets comprising tamsulosin and solifenacin
KR20250022143A (ko) 피미테스핍을 함유하는 의약 조성물
JP2021518422A (ja) レナリドミドを含む医薬組成物
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
JP2017210435A (ja) イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
EP4302755B1 (en) Palbociclib formulation containing an amino acid
EP3843702B1 (en) Immediate release fixed-dose combination of memantine and donepezil
HK40115959A (zh) 含有匹米替比的医药组合物
JP6858873B2 (ja) セレコキシブを含む錠剤
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20250107

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250107

Comment text: Request for Examination of Application

PG1501 Laying open of application